Should hormone replacement therapy be started in a perimenopausal woman with moderate to severe vasomotor symptoms and no contraindications?

Should HRT Be Started During Perimenopause?

Yes, hormone replacement therapy should be started during perimenopause for women with moderate to severe vasomotor symptoms who have no contraindications, as this represents the optimal therapeutic window with the most favorable benefit-risk ratio.

The Timing Advantage

Starting HRT during perimenopause or early menopause (within 10 years of menopause onset or before age 60) is strongly supported by the "timing hypothesis" - the concept that estrogen provides cardiovascular protection and other benefits when initiated early, but these advantages diminish or reverse when started later 1, 2. For women under 60 or within 10 years of menopause onset without contraindications, the benefit-risk ratio is favorable for treating bothersome vasomotor symptoms 2.

The evidence is particularly compelling when you consider what happens with delayed initiation. Women who start HRT after age 65 face significantly increased risks: a 2.2-fold increase in cancer risk and a 2.7-fold increase in cerebrovascular events 3. In contrast, perimenopausal initiation allows women to benefit from symptom relief while avoiding these late-initiation hazards.

Treatment Selection Algorithm

For women WITH a uterus:

• Use estrogen plus progestogen therapy (EPT)
• Prefer transdermal estradiol combined with micronized progesterone for women with moderate cardiovascular risk, as these preparations have fewer adverse metabolic effects 1
• Alternative: conjugated equine estrogens/bazedoxifene combination where available 1

For women WITHOUT a uterus:

• Use estrogen therapy (ET) alone
• Transdermal formulations preferred if any cardiovascular risk factors present 1

Critical Risk Stratification

Before initiating HRT during perimenopause, assess baseline cardiovascular disease risk 1:

High CVD risk: Use nonhormonal therapies (SSRIs/SNRIs, gabapentin, or pregabalin) instead of HRT 1

Moderate CVD risk: Transdermal estradiol is first-line, combined with micronized progesterone if uterus present 1

Low CVD risk: Standard HRT formulations appropriate

Common Pitfalls to Avoid

1. Don't use custom-compounded hormones - stick with FDA-approved preparations 1

2. Don't add progestogen unnecessarily - women without a uterus should receive estrogen-only therapy

3. Don't delay treatment waiting for "true menopause" - perimenopausal symptoms warrant treatment, and early initiation is safer than late initiation 4, 5

4. Don't forget annual reassessment - the decision to continue should be revisited yearly, targeting the shortest duration consistent with treatment goals 1

The Evidence Landscape

While the 2015 Endocrine Society guidelines 1 provide the foundational framework, more recent evidence from 2022-2026 reinforces the timing hypothesis. The 2022 NAMS position statement 2 explicitly states that for women under 60 or within 10 years of menopause, the benefit-risk ratio is favorable. The 2026 research 3 provides stark contrast by showing the dangers of late initiation (after 65), with hazard ratios exceeding 2.0 for major adverse events.

The key message: perimenopause is not too early - it's actually the ideal time to start HRT for symptomatic women without contraindications. The protective cardiovascular effects, bone preservation, and quality of life improvements are maximized when therapy begins during this window 4, 6, 5.

Monitoring Requirements

• Inform patients about increased breast cancer risk with EPT and ensure age-appropriate screening 1
• Evaluate any unscheduled bleeding promptly to rule out endometrial pathology 1
• Use shared decision-making for formulation choice, dose, and route of administration 1